Large Scale Manufacturing of TXU(Anti-CD7)-Pokeweed Antiviral Protein (PAP) Immunoconjugate for Clinical Trials

References

• Ching-Hon Pui, Behm F.G., Singh B., Schell M.J., Williams D.L., Rivera G.K., Kalwinsky D.K., Sandlund J.T., Crist W.M., Raimondi S.C. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990; 75: 174–179
   PubMed Web of Science ®Google Scholar
• Trigg M., Gaynon P., Uckun F.M. Acute lymphoblastic leukemia in children [in] cancer medicine. 4th Edition, J.F. Holland, R.C. Bast, D.Z. Morton, E. Foei, D.W. Kufer, R.R. Weichselbaum, 1996; 2945–2960, Chapter 164
   Google Scholar
• Smith M., Arthur D., Camitta B., Carroll A.J., Crist W., Gaynon P., Gelber R., Heerema N., Korn E.L., Link M., Murphy S., Pui C.H., Pullen J., Reaman G., Sallan S.E., Sather H., Shuster J., Simon R., Trigg M., Tubergen D., Uckun F.M., Ungerleider R. Uniform approach to risk classification and treatment assignment for Children with acute lymphoblastic leukemia. Journal of Clinical Oncology 1996; 14(1)18–24
   PubMed Web of Science ®Google Scholar
• Uckun F.M. Biology and treatment of T-cell acute lymphoblastic leukemia (review). Blood 1996, in press
   Google Scholar
• Vitetta E.S., Fulton R.J., May R.D., Till M., Uhr J.W. Redesigning nature's poisons to create anti-tumor reagents. Science 1987; 238: 1098–1104
   PubMed Web of Science ®Google Scholar
• Uckun F.M. Immunotoxins for the treatment of leukemia (Review). Brit J Haematol 1993; 85: 435–438
   PubMed Web of Science ®Google Scholar
• Grossbard M.L., Nadler L.M. Immunotoxin therapy of lymphoma. Cancer Treatment and Research 1993; 68: 111–131
   PubMedGoogle Scholar
• Preijers F. W. M. B., De Witte T., Wessels J.M.C., De Gast G.C., Van Leeuwen E., Capel F.J.A., Haanen C. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WTI-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 1989; 74: 1152–1158
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Kersey J.H., Vallera D.A., Ledbetter J.A., Weisdorf D., Myers D.E., Haake R., Ramsay N.K.C. Autologous bone marrow transplantation in high risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–1733
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Gajl-Peczalska K.J., Myers D.E., Ramsay N.K.C., Kersey J.H., Colvin M., Vallera D.A. Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. Blood 1987; 69: 361–366
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Myers D.E., Ledbetter J.A., Swaim S.E., Gajl-Peczalska K.J., Vallera D.A. Use of colony assays and anti-T-cell immunotoxins to elucidate the immuno-biologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia. Journal of Immunology 1988; 140: 2103–2111
   PubMed Web of Science ®Google Scholar
• Ramakrishman S., Uckun F.M., Houston L.L. Anti-T-cell immunotoxins containing pokeweed antiviral protein: potential purging agents for human autologous bone marrow transplantation. Journal of Immunology 1985; 135: 3516–3522
   Google Scholar
• Stong R.C., Uckun F.M., Youle R.J., Kersey J.H., Vallera D.A. Use of multiple T-cell directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 1985; 66: 627–635
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Ramakrishnan S., Houston L.L. Ex vivo elimination of neoplastic T-cells from human marrow using an anti-mr 41, 000 protein immunotoxin: potentiation by ASTA Z 7557. Blut 1985; 50: 19–23
   PubMedGoogle Scholar
• Gunther R., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Irvin J.D., Myers D.E., Uckun F.M. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia 1993; 7: 298–309
   PubMed Web of Science ®Google Scholar
• Waurzyniak B., Schneider E.A., Yanishevski Y., Gunther R., Chelstrom L.M., Wendorf H., Myers D.E., Irvin J.D., Messinger Y., Ek O., Zeren T., Chandan-Langlie M., Evans W.E., Uckun F.M. In vivo toxicity, pharmacokinetics, and anti-leukemic activity of TXU (anti-CD7)-pokeweed antiviral protein (PAP) immunotoxin. Clin. Cancer Research 1996, submitted
   Web of Science ®Google Scholar
• Myers D.E., Irvin J.D., Smith R.S., Kuebelbeck V.M., Uckun F.M. Production of a pokeweed antiviral protein (PAP) containing immunotoxin, B43-PAP, against the CD19 human B-lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J. Immunol. Methods 1991; 136: 221–238
   PubMed Web of Science ®Google Scholar
• Edman P., Begg G. A protein sequenator. Eur. J. Biochemistry 1967; 1: 80–90
   PubMedGoogle Scholar
• Hunkapiller M.W., Hewick R.M., Dreyer W.J., Hood L.E. High-sensitivity sequencing with a gas-phase sequenator. Methods in Enzymology 1983; 91: 399–413
   PubMed Web of Science ®Google Scholar
• Pelham H.R.B., Jackson R.J. An efficient mRNA-dependent translation system from reticulocyte lysates. Eur. J. Biochem 1976; 67: 247–250
   PubMedGoogle Scholar
• Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Towbin H., Staehlin T., Gordon J. Electro-phoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 1979; 76: 4350–4354
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Ramakrishnan S., Houston L.L. Increased efficiency in selective elimination of leukemic cells by combination of a stable derivative of cyclophosphamide and a human B-cell specific immunotoxin containing poke-weed antiviral protein. Cancer Research 1985; 5: 69–75
   Google Scholar
• Uckun F.M., Stong R., Youle R.J., Vallera D.A. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T-cells from autologous marrow grafts. journal of Immunology 1985; 134: 3504–3515
   PubMed Web of Science ®Google Scholar
• Irvin J.D., Uckun F.M. Pokeweed antiviral protein: ribosomal inactivation and therapeutic applications. Pharmacology & Therapeutics 1992; 55: 279–302
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Reaman G., Steinherz P.G., Arthur D.C., Sather H., Trigg M., Tubergen D., Gaynon P. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a children's cancer group study. Leukemia & Lymphoma 1996, in press
   Web of Science ®Google Scholar
• Pastan I., Willingham M.C., FitzGerald D.J.P. Immunotoxins. Cell 1986; 47: 641
   PubMed Web of Science ®Google Scholar
• Neville D.M., Youle R.J. Monoclonal antibody-ricin or ricin A chain hybrids. Kinetic analysis of cell killing for tumor therapy. Immunol. Rev. 1982; 62: 75
   PubMed Web of Science ®Google Scholar
• Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N.F., Watson G.J., Knyba R.E., Wawrzynczak E.J., Blakey D.C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability. in vivo, Cancer Res. 1987; 47: 5924
   PubMed Web of Science ®Google Scholar
• Blakey D.C., Skilleter D.N., Price R.J., Watson G.J., Hart L.I., Newell D.R., Thorpe P.E. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin. A chain immunotoxins on murine liver parenchymal cells. Cancer Res. 1988; 48: 7072
   PubMed Web of Science ®Google Scholar
• Sivam G., Pearson J.W., Bohn W., Oldham R.K., Sadoff J.C., Morgan A.C., Jr. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates. Cancer Res. 1987; 41: 3169
   Google Scholar
• Uckun F.M., Yanishevski Y., Waurzyniak B., Messinger Y., Chelstrom L.M., Schnneider E.A., Ek O., Zeren T., Haissig S., Langlie M., Irvin J.D., Myers D.E., Evans W., Gunther R. Pharmacokinetic features, immunogenicity and toxicity of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Clin. Cancer Research 1996, in press
   PubMed Web of Science ®Google Scholar
• Myers D.E., Yanishevski Y., Masson E., Irvin J.D., Evans W.E., Uckun F.M. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Leukemia and Lymphoma 1995; 18: 93–102
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Myers D.E., Irvin J.D., Kuebelbeck V.M., Finnegan D., Chelstrom L.M., Houston L.L. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity, and anti-leukemic activity of B43 (anti-CD 19) pokeweed antiviral protein immunotoxin. Leukemia and Lymphoma 1993; 9: 459–476
   PubMed Web of Science ®Google Scholar